Why Good Strategies Die in Capital Review

2 days ago
8 min read

Most health systems do not struggle to generate ideas. They struggle to get the right ideas funded.

That distinction matters more than most strategy conversations admit.

In many organizations, the strategy itself sounds convincing. The ambition is clear. The narrative is strong. Leaders can see the opportunity. Everyone agrees the initiative is aligned with the future of the system.

And then the conversation shifts.

The capital committee starts asking harder questions.

What is the ROI? What assumptions are carrying the case? How sensitive is the upside to those assumptions? What dependencies could delay value? What do we give up if we fund this now instead of something else? What is the cost of being wrong? What does success look like in twelve months, and how will we know?

That is where many otherwise promising strategies begin to weaken.

Not because the idea is bad. Because the logic underneath it is too fragile.

This is one of the biggest blind spots in healthcare strategy today. Too many initiatives are discussed as strategic priorities before they are built as decision-grade cases. They are approved in spirit, but not yet underwriteable in practice.

That is why good strategies so often die in capital review.

The Tell: Five Signs a Strategy Will Not Survive Scrutiny

Before an initiative ever reaches the committee, the warning signs are usually visible. Look for these patterns in the cases circulating in your organization right now.

The value range is a single number, not a range. If a case shows one ROI figure with no scenario logic, the team has not yet stress-tested the upside or the downside. They have produced an estimate, not a decision.
The benefits are described in language, not in mechanics. "Improved throughput" or "better patient experience" without the underlying volume, rate, mix, or cost lever is a story, not a model. Decision-grade cases name the lever, the magnitude, and the path to realization.
The assumptions are not separated from the conclusions. When you cannot tell which inputs are driving which outputs, the case cannot be challenged or updated. It can only be accepted or rejected wholesale.
The timing of value is unspecified. "Year one breakeven" without a phasing curve, ramp assumptions, or adoption trajectory means the team has not yet thought through how value actually arrives. Most healthcare initiatives realize value in the back half of year two at the earliest. Cases that ignore this almost always overstate near-term return.
The case has never been compared to other cases on shared logic. If three initiatives use three different definitions of ROI, three different time horizons, and three different assumption frameworks, leadership is not prioritizing. They are choosing whichever case sounds most compelling in the room.

That is not capital allocation. That is persuasion.

And persuasion is a weak foundation for enterprise decision-making.

What the Market Already Knows

Deloitte's work on digital transformation in healthcare points directly at this tension. It describes the challenge health leaders face in identifying and measuring ROI from digital initiatives and says Deloitte developed a Digital Transformation Value Database with approximately 50 individual levers across seven categories to help quantify value more consistently.

That alone tells you the market already recognizes the problem: leaders are not just struggling to choose what sounds promising. They are struggling to compare investments with enough rigor to fund them confidently.

This is not a minor process issue. It is the point where strategy either becomes real or remains a narrative.

A strategy is only real when it can survive scrutiny from finance, operations, and governance. Until then, it is still an ambition. Still a story. Still a directional bet waiting to be translated into something the enterprise can actually underwrite.

That translation is where many teams fall short.

Some initiatives rely on assumptions that are too vague. Some rely on value claims that are directionally attractive but not decision-ready. Some lack enough clarity around timing, adoption, or operational dependencies. Some are never compared on shared logic.

What a Decision-Grade Case Actually Contains

If a strategy is going to survive capital review, the case underneath it has to do seven things. Not eventually. Before it ever reaches the committee.

It names the value levers explicitly. Volume, rate, mix, throughput, length of stay, denial rate, contribution margin, labor productivity, capital avoidance. Whatever the lever is, it should be specific enough that finance can audit it and operations can own it.
It quantifies a value range, not a point estimate. A base, a downside, an upside, and the assumption shifts that move the case between them. If a 10% change in adoption flips the ROI from positive to negative, leadership needs to know that before the bet is placed.
It separates assumptions from conclusions. Every material number in the case should be traceable to an explicit input that someone is willing to defend, revise, or refute.
It phases the value over time. Year one, year two, year three. Ramp curves. Adoption assumptions. The dependencies that gate each phase.
It identifies the operational pre-conditions for value capture. Workflow change, staffing model, IT integration, governance, contracting, training. If the value depends on five things going right and only two are in motion, the case is not yet fundable.
It compares the initiative to its real alternatives, including doing nothing. Opportunity cost is the most consistently underweighted variable in healthcare capital planning.
It defines the leading indicators that will tell leadership whether the bet is working. Not annual ROI. The two or three operational signals that will appear in months one through six and either confirm or reset the trajectory.

When all seven are present, the case is underwriteable. When any are missing, the conversation in the committee will reliably stall on the gap.

The Counterexample: Discipline as the Differentiator

The best counterexample to fragile cases is not a prettier business case. It is a more disciplined process.

Premier's Kaleida Health case is useful here because it shows what happens when evaluation becomes structured and repeatable. Premier says Kaleida Health recognized more than $17.7 million in savings in 2022 from its data-driven value analysis methodology and process, and more than $75 million over five years overall. Just as important, the case ties those results to a systemwide, physician-led decision-making structure, integrated data, and a trusted process for leaders and clinicians to make decisions together.

That is the real lesson.

The win is not just the savings number. The win is that the organization built a decision structure capable of producing those outcomes repeatedly.

It moved from one-off evaluation to shared decision logic. It created a way for financial, clinical, and operational considerations to meet inside the same process. It made the next case easier to build than the last one, because the scaffolding was already in place.

That is what many health systems are still missing upstream.

They are trying to improve prioritization without first improving the quality of the case entering prioritization. They are trying to speed up governance without making initiatives more comparable. They are trying to make better bets without a disciplined way to test assumptions before the bet is placed.

Five Disciplines That Make Strategies Underwriteable

If the goal is to stop losing good strategies in capital review, five disciplines have to become standard practice. Not for the largest initiatives. For every initiative that touches enterprise capital.

A shared definition of value across the system. Finance, strategy, operations, and clinical leadership working from one definition of how an initiative creates value, expressed in the same units, over the same time horizon. Without this, every case becomes a translation exercise and translations leak meaning.
A consistent assumption library. The volume, rate, adoption, labor, and unit-cost assumptions that recur across initiatives should be maintained centrally and updated as evidence accumulates. New cases inherit the library and justify any deviation. This single practice does more to compress capital review cycle time than any other.
A standard sensitivity protocol. Every case identifies the three to five assumptions most material to the outcome and shows how the case shifts when each is moved. Committees stop debating point estimates and start debating which assumptions deserve the most scrutiny.
A pre-mortem on operational dependencies. Before the case is finalized, the team identifies the five most likely reasons the initiative will not capture its projected value, and what would have to be true to prevent each. This is the discipline that converts ambition into a delivery plan.
A leading-indicator dashboard tied to the case.
The same numbers that drove the ROI in the case become the numbers leadership watches for the first six months. The case is not closed when capital is approved. It is closed when the leading indicators have either confirmed or reset the trajectory.

These five disciplines are the difference between a strategy process and decision infrastructure.

What to Do in the Next 90 Days

The shift from persuasion to underwriting does not require a transformation program. It requires a small number of deliberate moves.

Audit the last six initiatives that went to capital review. For each, score the seven elements of a decision-grade case. The pattern of gaps will tell you exactly where your upstream process is leaking rigor.

Pick one in-flight initiative and rebuild its case to the seven-element standard. Use it as the reference template for the next planning cycle. The point is not to redo the work. It is to give the organization a concrete example of what decision-grade looks like in your context.

Establish the assumption library for the three to five levers that show up most often in your capital cases. Volume growth assumptions, labor productivity assumptions, adoption ramps, denial rates, contribution margin standards. Centralize them. Date them. Version them.

Add a one-page sensitivity summary to every case format going forward. The three assumptions that move the outcome most, and the range over which they move it. Make this non-negotiable for committee submission.

Define and assign owners for the leading indicators on every approved case. The financial close on the case is no longer the end of the process. The first review of the leading indicators, ninety days post-approval, is.

None of this is exotic. None of it requires new technology to begin. What it requires is the decision that strategic intent must be translated into decision-grade logic before it enters the room, not after.

The Deeper Reason

This is why ROI should not be treated as a downstream validation exercise.

It should shape prioritization from the start.

By the time an initiative reaches capital review, the organization should already know:

what value range is plausible
what assumptions matter most
what would make the case stronger or weaker
what risks or dependencies threaten delivery
what trade-offs are created by funding it now
what leading indicators will tell us in 90 days whether the bet is working

Without that structure, capital review becomes a cleanup exercise for upstream ambiguity.

And that is expensive.

It slows decisions. It weakens trust between strategy and finance. It increases rework. It forces leaders to re-litigate logic that should already have been made explicit. It creates a pattern where the loudest case wins instead of the strongest one.

This is the deeper reason good strategies die in capital review.

They are not dying because the organization lacks vision. They are dying because the organization lacks a consistent way to turn strategic intent into decision-grade logic.

That is the difference between having a strategy process and having decision infrastructure.

One produces direction. The other produces fundable choices.

The systems that consistently turn strategy into capital are not the ones with the most ambitious ideas. They are the ones that have built the discipline to make every idea underwriteable before it is debated.

That is the work. And it starts upstream of the committee, not inside it.

_____

When the pressure is high and the room wants answers, clearer logic changes everything. If you are tired of defending high-stakes decisions with slides, fragments, and gut feel, start here. See how our Strategy Intelligence Platform helps you bring stronger logic, clearer trade-offs, and more defensible recommendations into the room. Download Sample Decision Artifacts here.